A Combined and Intensive Exercise Model Improves Physical Capacity in Cardiac Patients
Journal Title: UNKNOWN - Year 2017, Vol 7, Issue 5
Abstract
Objective: We have measured the effect of combined strength and high intensity endurance training on physical capacity and lipid profile in patients with heart and coronary diseases. We wanted to see whether cardiac patients were able to increase training intensity to improve strength without losing endurance capacity. Methods: Thirty heart-operated subjects participated in an intervention period of 10 weeks. The age of the participants was between 52-72 years. The Resistance-Interval group (RE-INT) practiced four times a week with two intensive endurance (spinning) sessions and two strength training sessions. The endurance training consisted of intervals where the heart rate reached>90% of maximum heart rate. Strength training was performed in three series with a load of 8-12 repetition maximum (RM). The subjects in the control group (CON) performed two to three sessions per week according to a national program specialized for coronary patients (called “Ullevaal model”). We had a randomized controlled trial. Results: Maximal leg strength increased in both groups during the intervention, but the increase was higher in the RE-INT group (from 107.9 ± 8.1 kg to 162.0 ± 8.4 kg) compared to the CON group (from 110.8 ± 8.9 to 125.4 ± 9.5 ) (p<0.001). Strength in chest press, the maximal oxygen uptake and the concentration of high densitylipoprotein (HDL) protein increased in both groups during the test period. However, no differences were observed between the RE-INT and CON group. Low density-lipoprotein (LDL), blood pressure and body weight did not change during the intervention period in any of the groups. Conclusion: cardiac patients were able to increase training intensity, strength and maximal oxygen uptake during a period of 10 weeks. We found that combined training has an effective impact on the increase in leg strength. The increase in muscle strength can be vital for the everyday quality of life in cardiac patients.
Authors and Affiliations
Ole Sveen, Arne Skaug, Trine Eker Christoffersen, Knut-Egil Hanssen, Jørgen Jensen
Keywords
Related Articles
- EP ID EP387006
- DOI 10.4172/2167-0870.1000326
- Views 73
- Downloads 0
Preparation with Mechanical Bowel Cleansing or/and Oral Antibiotics or Nothing for Elective Colorectal Surgery: Two-Two-Arm Multicentre Randomised Controlled Studies (MECCLANT –C and –R Trials)
Background: Based on sound evidence, traditional mechanical bowel preparation for elective colorectal surgery has mostly been abandoned during the last two decades. However, more recent evidence from USA large databases...
Feasibility Study of Bolus 5-Fluorouracil+L-Leucovorin as Salvage Line Chemotherapy for Oral Fluorouracil-Resistant Unresectable Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group Study HGCSG1502
In November 2015 we began a feasibility study of salvage line chemotherapy with 5-fluorouracil and l-leucovorin given in an intravenous bolus once weekly followed by a 2-week rest period within a 8-week cycle in patients...
Extraskeletal Myxoid Chondrosarcoma: A Case Report
Extraskeletal myxoid chondrosarcoma (EMCS) is a rare malignant soft tissue tumor that usually develops in the deep parts of the proximal extremities and limb girdles in middle-aged adults. Its biologic behavior and patho...
Being Principal Investigators on Pharma-initiated Clinical Trials: Have we Sold Ourselves Too Cheap?
The other day in clinic I was going through one of those good-clinical-practice (GCP) modules, as requested by one of the pharma companies in order for me to participate as an investigator in one of their clinical trial....
Nivolumab Maintenance as Monotherapy after Carboplatin Plus Nab- Paclitaxel for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Study Protocol for Feasibility
The aim of this study is to determine the feasibility of nivolumab as maintenance therapy after first-line chemotherapy with carboplatin plus nab-paclitaxel in non-small-cell lung cancer. Since we cannot change the dose...